NCT07077395View on ClinicalTrials.gov

Finding Links Between Hot flASHes and CardioVascular Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2030

Conditions
Menopause-related Hot Flashes
Interventions
DRUG

fezolinetant - reference formulation

fezolinetant 45 mg daily x 12 weeks

DRUG

placebo

placebo daily x 12 weeks

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER